[1] Eisman, J. A. , Bogoch, E. R. , Dell, R. , Harrington, J. T. , Mckinney, R. E. , & Mclellan, A. , et al. (2012). Making the first fracture the last fracture: asbmr task force report on secondary fracture prevention. Journal of Bone & Mineral Research, 27(10), 2039-2046.
[2] Black, D. M. , & Rosen, C. J. . (2016). Clinical practice. Postmenopausal osteoporosis.
[3] Zebaze, R. M. , Libanati, C. , Austin, M. , Ghasem-Zadeh, A. , & Seeman, E. . (2013). Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone, 59(2), 173-179.
[4] Oswald, A. J. , Berg, J. , Milne, G. , & Ralston, S. H. . (2014). Teriparatide treatment of severe osteoporosis reduces the risk of vertebral fractures compared with standard care in routine clinical practice. Calcified Tissue International, 94(2), 176.
[5] Walsh, J. B. , Lems, W. F. , Karras, D. , Langdahl, B. L. , Ljunggren, O. , & Fahrleitner-Pammer, A. , et al. (2012). Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the european forsteo observational study (efos). Calcif Tissue Int, 90(5), 373-383.
[6] Adler, & Robert, A. . (2018). Update on Osteoporosis in Men.
[7] Tanaka, I. , Tanaka, Y. , Soen, S. , & Oshima, H. . (2020). Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the tower-go study. Journal of Bone and Mineral Metabolism, 1-10.
[8] Huang, S. , Lin, H. , Zhu, X. , Chen, X. , Fan, L. , & Liu, C. . (2014). Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in chinese women with postmenopausal osteoporosis. Endokrynologia Polska, 65(2), 96-104.
[9] Maricic, M. . (2010). The role of zoledronic acid in the management of osteoporosis. Clinical Rheumatology, 29(10), 1079-1084.
[10] Dhillon, S. . (2016). Zoledronic acid (reclast®, aclasta®): a review in osteoporosis. Drugs.
[11] John, M. T. , Sims, N. A. , & Ego, S. . (2021). Physiological and pharmacological roles of pth and pthrp in bone using their shared receptor, pth1r. Endocrine Reviews.
[12] Kim SW, Pajevic PD, Selig M, Barry KJ, Y ang JY , Shin CS, Baek WY , Kim JE, Kronenberg HM. . (2012). Intermittent parathyroid hormone administration converts quiescent lining cells to active osteoblasts. Journal of Bone and Mineral Research, 27(10).
[13] Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. .(2003). Proteasomal degradation of runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. a putative explanation for why intermittent administration is needed for bone anabolism. Journal of Biological Chemistry, 278(50), 50259-72.
[14] Zhang, W. , Zhu, J. , Ma, T. , Liu, C. , Hai, B. , & Du, G. , et al. (2017). Comparison of the effects of once‐weekly and once‐daily rhpth (1–34) injections on promoting fracture healing in rodents. Journal of Orthopaedic Research.
[15] Rowshan, H. H. , Parham, M. A. , Baur, D. A. , Mcentee, R. , Cauley, E. , & Carriere, D. T. , et al. (2010). Effect of intermittent systemic administration of recombinant parathyroid hormone (1-34) on mandibular fracture healing in rats. J Oral Maxillofac Surg, 68(2), 260-267.
[16] A, M. K. , A, E. K. S. , B, C. W. , C, M. W. , A, L. K. , & A, S. S. , et al. (2010). Effect of human parathyroid hormone hpth (1–34) applied at different regimes on fracture healing and muscle in ovariectomized and healthy rats. Bone, 47( 3), 480-492.
[17] Seeman, E. , & Martin, T. J. . (2015). Co-administration of antiresorptive and anabolic agents: a missed opportunity. Journal of Bone & Mineral Research the Official Journal of the American Society for Bone & Mineral Research, 30(5), 753-764.
[18] Liu, Z. D. , Tao, J. C. , Yi, X. , & Zhang, C. Y. . (2009). Associations of age-related expression changes of peroxisome proliferator-activated receptor gamma and core binding factor alpha 1 in bone marrow cells with age-related fracture healing impairment in rats. Journal of Clinical Rehabilitative Tissue Engineering Research.
[19]Vandenbroucke, F P, Luyten, Flamaing, & Gielen. (2017). Pharmacological treatment of osteoporosis in the oldest old. Clinical interventions in aging.
[20] Dempster, D. W. , Roschger, P. , Misof, B. M. , Zhou, H. , Paschalis, E. P. , & Alam, J. , et al. (2016). Differential effects of teriparatide and zoledronic acid on bone mineralization density distribution at 6 and 24 months in the shotz study. Journal of Bone & Mineral Research the Official Journal of the American Society for Bone & Mineral Research, 1527-1535.
[21] Wei, Y. , Miao, Y. , & Liu, Z. . (2007). Clinical progress in biochemical markers for bone metabolism—review in biochemical markers for bone metabolism in different countries and regions in premenopausal and postmenopausal women. Chinese Journal of Osteoporosis.
[22] Kyvernitakis, I. , Saeger, U. , Ziller, V. , Bauer, T. , Seker-Pektas, B. , & Hadji, P. . (2013). The effect of age, sex hormones, and bone turnover markers on calcaneal quantitative ultrasonometry in healthy german men. Journal of Clinical Densitometry, 16(3), 320-328.
[23] Shi, Z. , Jin, H. , Ding, Q. , Ying, J. , & He, B. . (2019). Bone turnover markers may predict the progression of osteonecrosis of the femoral head in aged males. Annals of Translational Medicine, 7(22), 626-626.
[24] Prince, R. , Sipos, A. , Hossain, A. , Syversen, U. , Ish-Shalom, S. , & Marcinowska, E. , et al. (2010). Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. Journal of Bone and Mineral Research, 20(9), 1507-1513.
[25] Hadji, P. , Zanchetta, J. R. , Russo, L. , Recknor, C. P. , Saag, K. G. , & Mckiernan, F. E. , et al. (2012). The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures. Osteoporosis International, 23(8), 2141-2150.
[26] Ito, A. , Iimura, T. , Lee, J. W. , Shimazu, Y. , & Takao-Kawabata, R. . (2020). Teriparatide relieves ovariectomyinduced hyperalgesia in rats, suggesting the involvement of functional regulation in primary sensory neurons by pth-mediated signaling. Scientific Reports, 10(1), 5346.
[27] A. J. Roelofs, K. Thompson, F. H. Ebetino, M. J. Rogers, F. P. Coxon. (2010). Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Current Pharmaceutical Design, 16(27), -.
[28] Baron, R. , Fe Rrari, S. , & Russell, R. . (2011). Denosumab and bisphosphonates: different mechanisms of action and effects. Bone, 48(4), 0-692.
[29] Cai, G. , Laslett, L. L. , Aitken, D. , Halliday, A. , Pan, F. , & Otahal, P. , et al. (2018). Effect of zoledronic acid and denosumab in patients with low back pain and modic change: a proof‐of‐principle trial. Journal of Bone & Mineral Research.
[30]Tan Jinmei,Bao Lihua,Ma Yuwei,et al. (2010). The comparison of the clinical outcomes between parathyroid hormone and calcitonin in short-term treatment of postmenopausal osteoporosis. Acta UnivMed Nanjing, 30(5):709-712